Overview of the results of recent beta blocker trials

Current Opinion in Cardiology

Volumn 16, Issue 3, 2001, Pages 180-185

  Tendera, Michal ^a   Ochala, Andrzej ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INOTROPIC AGENT; METOPROLOL;

CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; GERIATRIC PATIENT; HEART FAILURE; HEART INFARCTION; HUMAN; MORTALITY; PRIORITY JOURNAL; REVIEW; SURVIVAL;

ADRENERGIC BETA-ANTAGONISTS; HEART FAILURE, CONGESTIVE; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 0035010033     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200105000-00004     Document Type: Review

References (47)

1. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy
2. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade
3. A rationale for the use of beta-blockers as standard treatment for heart failure
4. Beta-adrenergic receptor blockade in chronic heart failure
5. Beta blocker treatment in heart failure
6. Importance of neuroendocrine activation in chronic heart failure. Impact on treatment strategies
7. Effects of beta-blocker therapy on mortality in patients with heart failure: A systematic overview of randomized controlled trials
8. Clinical effects of beta-adrenergic blockade in chronic heart failure: A meta-analysis of double-blind, placebo-controlled, randomized trials
9. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
10. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure
11. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure
12. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure
13. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
14. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
15. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
16. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure
17. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure
18. Metoprolol: A review of its use in chronic heart failure
19. Consensus recommendations for the management of chronic heart failure
20. Predictors of medical events in patients enrolled in the Cardiac Insufficiency Bisoprolol Study (CIBIS): A study of the interactions between beta-blocker therapy and occurrence of critical events using analysis of competitive risk
21. Beta-blocker therapy in advanced heart failure: Clinical characteristics and long-term outcomes
22. Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure
23. Carvedilol improves functional class in patients with severe left ventricular dysfunction referred for heart transplantation
24. Design of the Beta-blocker Evaluation Survival Trial (BEST)
25. Effects of carvedilol on the survival of patients with severe chronic heart failure
26. Beta-adrenergic blocking agents in heart failure. Benefits of vasodilating and nonvasodilating agents according to patients' characteristics: A meta-analysis of clinical trials
27. Treatment of heart failure with celiprolol, a cardioselective beta blocker with beta-2 agonist vasodilatory properties
28. Beta-blockade in heart failure: A comparison of carvedilol with metoprolol
29. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure
30. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol
31. The epidemiology of heart failure: The Framingham study
32. Treatment of congestive heart failure. Has the time come for decreased complexity?
33. Ageing and heart failure; the place of ACE inhibitors in heart failure with preserved systolic function
34. Heart failure associated with preserved systolic function: A common and costly clinical entity
35. Incidence and etiology of heart failure: A population-based study
36. Effect of concomitant digoxin and carvedilol therapy on mortality and morbidity in patients with chronic heart failure
37. Combination therapy with carvedilol and amiodarone in patients with severe heart failure
38. Impact of concurrent amiodarone treatment on the tolerability and efficacy of carvedilol in patients with chronic heart failure
39. Effect of beta-1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril
40. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy. The randomized evaluation of strategies for left ventricular dysfunction pilot study
41. Are beta-blockers effective in patients who develop heart failure soon after myocardial infarction? A meta-regression analysis of randomized trials
42. Design and methodology of the CAPRICORN trial: A randomised, double blind, placebo-controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction
43. Screening, endpoint classification, and safety monitoring in the Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
44. Clinical trials update
45. Introducing new treatments in clinical practice: The Italian approach to beta-blockers in heart failure
46. Rationale, design and methods for a Coreg (carvedilol) Heart Failure Registry (COHERE)
47. Team management of patients with heart failure. A statement for health care professionals from the Cardiovascular Nursing Council of the American Heart Association